{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:08:27Z","timestamp":1773234507918,"version":"3.50.1"},"reference-count":25,"publisher":"SLACK, Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pediatr Ophthalmol Strabismus"],"published-print":{"date-parts":[[1997,7]]},"abstract":"<jats:p>ABSTRACT<\/jats:p>\n          <jats:p>Purpose: To study the incidence, cause, recovery time, and prevention of diplopia following subcutaneous injection of botulinum A toxin for the treatment of facial spasms.<\/jats:p>\n          <jats:p>Methods: Patients who experienced diplopia after botulinum A toxin injections had their deviations examined in detail. When the muscle that caused diplopia was identifiable, the injection closest to that muscle was omitted in the next treatment in an attempt to prevent diplopia.<\/jats:p>\n          <jats:p>Results: Of 250 patients receiving about 1500 sets of injections, 25 (1.7%) incidents of diplopia occurred in 10 patients. Excluding two patients who declined further treatment after having diplopia on their first botulinum A toxin treatment, seven of the remaining eight patients had multiple incidents of diplopia. The most common pattern of diplopia was \"uncertain diagnosis.\" The most common identifiable cause of diplopia was paresis of the inferior oblique muscle. Omission of the injection into the central portion of the lower eyelids in the next treatment prevented recurrence of diplopia in only one of the four patients. No significant correlation between botulinum A toxin doses injected and times to recovery was noted.<\/jats:p>\n          <jats:p>Conclusions: Diplopia following botulinum A toxin treatment is uncommon. Seven patients (3% of patients studied) had 22 episodes of diplopia (88% of episodes). When diplopia occurs, it tends to recur on reinjection, sometimes with a prolonged recovery time. This response may not be dose dependent. The extraocular muscles of some patients may be more susceptible to chemodenervation than others, or botulinum A toxin may diffuse to extraocular muscles more easily in some patients than in others.<\/jats:p>","DOI":"10.3928\/0191-3913-19970701-10","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T22:49:35Z","timestamp":1618958975000},"page":"229-234","source":"Crossref","is-referenced-by-count":28,"title":["Diplopia Following Subcutaneous Injections of Botulinum A Toxin for Facial Spasms"],"prefix":"10.3928","volume":"34","author":[{"given":"Sorot","family":"Wutthiphan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Kowal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"O'Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_1","doi-asserted-by":"crossref","unstructured":"1. Elston JS. The clinical use of botulinum toxin. Seminars in Ophthalmology. 1988;3:249-260.","DOI":"10.3109\/08820538809063827"},{"key":"e_1_3_1_3_1","doi-asserted-by":"crossref","unstructured":"2. Duchen LW. Changes in the electron microscopic structure of slow and fast skeletal muscle fibers of the mouse after the local injection of botulinum toxin. J Neurosci. 1971;14:47 60.","DOI":"10.1016\/0022-510X(71)90129-8"},{"key":"e_1_3_1_4_1","doi-asserted-by":"crossref","unstructured":"3. Bates AK Halliday BL Bailey CS Collin JRO Bird AC. Surgical management of essential blepharospasm. Br J Ophthalmol. 1991;75:487490.","DOI":"10.1136\/bjo.75.8.487"},{"key":"e_1_3_1_5_1","unstructured":"4. Borodic GE. Hemifacial spasm: evaluation and managements with emphasis on botulinum toxin therapy. In: Jankovic J Hallett M eds. Therapy With Botulinum Toxin. New York NY: Marcel Dekker Ine; 1994:331-351."},{"key":"e_1_3_1_6_1","doi-asserted-by":"crossref","unstructured":"5. Jannetta PJ Abbasy M Maroon JC Ramos FM Albin MS. Etiology and definitive microsurgical treatment of hemifacial spasm. J Neurosurg. 1977;47:321-328.","DOI":"10.3171\/jns.1977.47.3.0321"},{"key":"e_1_3_1_7_1","doi-asserted-by":"crossref","unstructured":"6. Osako M Keltner JL. Botulinum A toxin (Oculinum) in ophthalmology. Surv Ophthalmol. 1991;36:28-46.","DOI":"10.1016\/0039-6257(91)90207-V"},{"key":"e_1_3_1_8_1","doi-asserted-by":"crossref","unstructured":"7. Grandes F Elston J Quinn N Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. 1988;51:767-772.","DOI":"10.1136\/jnnp.51.6.767"},{"key":"e_1_3_1_9_1","doi-asserted-by":"crossref","unstructured":"8. Dutton JJ Buckley KG. Long term results and complications of botulinum A toxin in the treatment of blepharospasm. Ophthalmology. 1988;95:1529-1534.","DOI":"10.1016\/S0161-6420(88)32977-5"},{"key":"e_1_3_1_10_1","unstructured":"9. Dutton JJ. Acute and chronic effects of botulinum toxin in the management of blepharospasm. In: Jankovic J Halle M eds. Therapy With Botulinum Toxin. New York NY: Marcel Dekker Ine; 1994:199-209."},{"key":"e_1_3_1_11_1","unstructured":"10. Scott AB. Botulinum treatment for blepharospasm. In: Smith BC Della Rocca RC Nesi FA Lisman RD eds. Ophthalmic Plastic and Reconstructive Surgery. St Louis Mo: CV Mosby; 1987:609-613."},{"key":"e_1_3_1_12_1","unstructured":"11. Patrinely JR Whiting AS Anderson RL. Local side effects of botulinum toxin injections. In: Jankovic J Tolosa E eds. Advances in Neurology. New York NY: Raven Press; 1988:49;493-500."},{"key":"e_1_3_1_13_1","unstructured":"12. Borodic GE Ferrante RJ Pearce LB Alderson K Pharmacology and histology of the therapeutic application of botulinum toxin. In: Jankovic J Hallett M eds. Therapy With Botulinum Toxin. New York NY: Marcel Dekker Ine; 1994:119-157."},{"key":"e_1_3_1_14_1","doi-asserted-by":"crossref","unstructured":"13. Borodic GE Cozzolino D Ferrante R Wiegner AW Young RR. Innervation zone of orbicularis oculi muscle and implications for botulinum A toxin therapy. Ophthalmic Plastic and Reconstructive Surgery. 1991;7:54-60.","DOI":"10.1097\/00002341-199103000-00007"},{"key":"e_1_3_1_15_1","doi-asserted-by":"crossref","unstructured":"14. Scott AB Kennedy RA Stubbs HA Botulinum A toxin injection as a treatment for blepharospasm. ArcA Ophthalmol. 1985;103:347-350.","DOI":"10.1001\/archopht.1985.01050030043017"},{"key":"e_1_3_1_16_1","doi-asserted-by":"crossref","unstructured":"15. Frueh BR Musch DC. Treatment of facial spasm with botulinum toxin: an interim report. Ophthalmology. 1986;93;917-923.","DOI":"10.1016\/S0161-6420(86)33641-8"},{"key":"e_1_3_1_17_1","doi-asserted-by":"crossref","unstructured":"16. Biglan AW May M Bowers RA Management of facial spasms with Clostridium botulinum toxin type A (Oculinum). Arch OtoL\u00b7ryngol Head Neck Surg. 1988;114:1407-1412.","DOI":"10.1001\/archotol.1988.01860240057024"},{"key":"e_1_3_1_18_1","doi-asserted-by":"crossref","unstructured":"17. Tsoy EA Buckley KG Dutton JJ. Treatment of blepharospasm with botulinum toxin. Am J Ophthalmol. 1985;99:176-179.","DOI":"10.1016\/0002-9394(85)90228-4"},{"key":"e_1_3_1_19_1","doi-asserted-by":"crossref","unstructured":"18. Kalra HK Magoon EH. Side effects of the use of botulinum toxin for treatment of benign essential blepharospasm and hemifacial spasm. Ophthalmic Surg. 1990;21:335-338.","DOI":"10.3928\/1542-8877-19900501-08"},{"key":"e_1_3_1_20_1","unstructured":"19. Taylor JDN Kraft SP Kazdan MS Flanders M Cadera W Orton RB. Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can J Ophthalmol. 1991;26:133138."},{"key":"e_1_3_1_21_1","doi-asserted-by":"crossref","unstructured":"20. Elston JS. Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injections. Br J Ophthalmol. 1987;71:664-668.","DOI":"10.1136\/bjo.71.9.664"},{"key":"e_1_3_1_22_1","unstructured":"21. Dietert SE. The demonstration of different types of muscle fibers in human extraocular muscle by electron microscopy and Cholinesterase staining. Invest Ophthalmol Vis Sci. 1965;4:51-63."},{"key":"e_1_3_1_23_1","doi-asserted-by":"crossref","unstructured":"22. Cheng K Cholinesterase activity in human extraocular muscles. Jpn J Ophthalmol. 1963;7:174-183.","DOI":"10.1001\/jama.1963.63700090034020b"},{"key":"e_1_3_1_24_1","unstructured":"23. Spencer RF McNeer KW. The periphery: extraocular muscles and motor neurones. In: RHS Carpenter ed. Vision and Visual Dysfunction. London: Macmillan Press; 1991;8:186-187."},{"key":"e_1_3_1_25_1","doi-asserted-by":"crossref","unstructured":"24. Engstrom PF Arnoult JB Mazow ML et al. Effectiveness of botulinum toxin therapy for essential blepharospasm. Ophthalmology. 1987;94:971-975.","DOI":"10.1016\/S0161-6420(87)33338-X"},{"key":"e_1_3_1_26_1","doi-asserted-by":"crossref","unstructured":"25. Shorr N Seiff SR Kopelman J. The use of botulinum toxin in blepharospasm. Am J Ophthalmol. 1985;99:542-546.","DOI":"10.1016\/S0002-9394(14)77954-1"}],"container-title":["Journal of Pediatric Ophthalmology &amp; Strabismus"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T23:14:32Z","timestamp":1683069272000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/0191-3913-19970701-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1997,7]]}},"alternative-id":["10.3928\/0191-3913-19970701-10"],"URL":"https:\/\/doi.org\/10.3928\/0191-3913-19970701-10","relation":{},"ISSN":["0191-3913","1938-2405"],"issn-type":[{"value":"0191-3913","type":"print"},{"value":"1938-2405","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,7]]}}}